Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Area of Science:

• Geriatric Psychiatry
• Neuroscience
• Pharmacology

Background:

• Elderly individuals face heightened psychosis risk due to age-related brain changes, comorbidities, and polypharmacy.
• Antipsychotic medication adherence is crucial for managing psychosis but challenging in older adults.
• Long-acting injectable antipsychotics present a viable alternative for patients with adherence difficulties.

Purpose of the Study:

• To evaluate the efficacy and safety of long-acting injectable antipsychotics in elderly patients.
• To address the challenges of medication adherence in older adults with psychosis.
• To explore the benefits of long-acting atypical antipsychotics in geriatric populations.

Main Methods:

• Review of existing studies on depot antipsychotics in elderly patients.
• Analysis of clinical data for long-acting injectable risperidone in older adults.
• Consideration of pharmacokinetic and pharmacodynamic factors in geriatric antipsychotic use.

Main Results:

• Long-acting injectable antipsychotics demonstrate positive outcomes in the elderly.
• Long-acting injectable risperidone showed significant clinical improvement compared to placebo.
• Treatment with long-acting injectable risperidone led to sustained reductions in hospitalization rates.

Conclusions:

• Long-acting injectable antipsychotic medication is a recommended option for long-term treatment in older patients with psychosis.
• The selection of specific long-acting injectable antipsychotics should consider patient history, preferences, and clinical experience.
• Long-acting atypical antipsychotics, like risperidone, offer a promising approach to managing psychosis in the elderly.